REMODEL: Semaglutide’s Kidney Effects on MRI and Biopsy in Type 2 Diabetes and CKD

In a 52-week randomized mechanistic trial, weekly semaglutide did not change the coprimary kidney MRI endpoints versus placebo, but secondary imaging, clinical, and tissue readouts point to lower renal vascular resistance, less fibrosis progression on diffusion MRI, lower albuminuria, and glomerular

NephroResource

Taking longer than expected

If you're on a slow connection or this keeps happening, tap below to reload.